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N-(3,5-Dimethylphenyl)-3-Methoxybenzamide
(A3B5) Targets TRP-2 and Inhibits Melanogenesis
and Melanoma Growth
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Melanin protects the skin from harmful environmental factors such as UV light. However, excessive melanin
production induces hyperpigmentation. Previously, N-(3,5-dimethylphenyl)-3-methoxybenzamide (A3B5), a
biaryl amide derivative, was identified for its ability to inhibit melanin production. However, its detailed
mechanism of action has not been investigated. We elucidated the inhibitory mechanisms of A3B5 in melanin
production. Our results showed that A3B5 had no effect on the production and activity of tyrosinase, an enzyme
involved in melanogenesis. However, A3B5 markedly decreased both constitutively expressed and UVB-induced
tyrosinase-related protein 2 (TRP-2), which plays an important role along with tyrosinase in melanogenesis. The
TRP-2 downregulation caused by A3B5 may occur through proteasomal degradation because the A3B5-induced
TRP-2 downregulation was inhibited by the ubiquitination inhibitor, MG-132. In addition, A3B5 inhibited the
proliferation of melanocytes and melanoma cells by arresting cells in the G1 stage of the cell cycle and
moderately suppressed tumor growth in vivo. Taken together, our results indicate that A3B5 downregulates
melanin production and melanoma cell growth via proteosomal degradation of TRP-2 and suggest that A3B5
can be a possible therapeutic agent that effectively regulates both hyperpigmentation and melanoma growth
in the skin.
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INTRODUCTION
Melanin is produced by melanocytes in the basal layer of the
epidermis and protects the skin from UV-induced damage.
However, overproduction of melanin leads to hyperpigmen-
tation in the skin (Hara et al., 1994). Melanogenesis is divided
into two pathways. Eumelanogenesis produces the black
pigment eumelanin, and pheomelanogenesis produces the
reddish to yellow pigment pheomelanin (Slominski, 2002).
Eumelanin synthesis in mammals involves at least three
enzymes: tyrosinase, tyrosinase-related protein-1 (TRP-1),
and tyrosinase-related protein-2 (TRP-2 or DOPAchrome
tautomerase) (Aroca et al., 1993). Tyrosinase is the first
enzyme in the melanin synthesis pathway, and it plays a role
in the regulation of melanin synthesis (Iozumi et al., 1993).
Melanin synthesis starts with the hydroxylation of L-tyrosine
to L-dihydroxyphenylalanine (L-DOPA), and the next step is
the oxidation of DOPA to DOPAquinone. TRP-2, which
functions as a DOPAchrome tautomerase, catalyzes DOPA-
chrome to 5,6-dihydroxyindole-2-carboxylic acid (DHICA),
and TRP-1 oxidizes DHICA to a carboxylated indole-
quinone. In particular, TRP-2 is an important regulatory
enzyme that plays a role in melanogenesis as well as in
melanocyte lineage and cell growth (Costin et al., 2005).
Moreover, overexpression of TRP-2 rescues melanocytes
from UVB-induced apoptosis (Nishioka et al., 1999). TRP-2
is also a marker for amelanotic and melanotic melanoma,
whereas tyrosinase and TRP-1 are absent in many amela-
notic melanomas (Orlow et al., 1998). Thus, TRP-2 can be a
good target for melanoma treatment. Indeed, it has been
reported that targeting TRP-2-containing cells with cytotoxic
T lymphocytes or antibody effectively inhibits melanoma cell
growth (Yamano et al., 2006). Therefore, a TRP-2 inhibitor
might be more effective than a tyrosinase inhibitor for treating
melanoma.
UVB is the most efficient stimulus for melanin produc-
tion in the skin (Kawaguchi et al., 2001). After exposure to
UVB, melanin moves to the surface of the epidermis, the
outermost layer of skin, and gives the skin a brownish
appearance. UVB is also involved in melanoma progression.
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It has been reported that UVB enhances melanoma cell
motility (Gebhardt et al., 2007) and induces TRP-2 expression
via mitogen-activated protein kinase and p38 activation in
the skin (Mizutani et al., 2005). Therefore, melanin produc-
tion and melanoma progression could be suppressed by the
downregulation of TRP-2.
Recently, we identified a potent and noncytotoxic
inhibitor of melanin production through parallel solution-
phase synthesis (Hwang et al., 2010). The selected com-
pound, N-(3,5-dimethylphenyl)-3-methoxybenzamide (A3B5),
which is a biaryl amide derivative and drug-like according to
Lipinski’s rule of five (Lipinski et al., 1997), exhibited an
inhibitory effect on melanin synthesis in Melan-a (a murine
melanocyte cell line) cells with low cell toxicity.
In this study, we investigated the inhibitory effect of A3B5
on melanin production. A3B5 effectively inhibited melanin
synthesis by degradation of TRP-2. Moreover, reduced level
of TRP-2 by degradation inhibited melanoma growth. These
results suggest that A3B5 can be used as an efficient thera-
peutic agent for hyperpigmentation and melanoma.
RESULTS
A3B5 inhibits melanin production in vivo and in vitro
We reported that A3B5 (Supplementary Figure S1a online) is a
depigmenting agent (Hwang et al., 2010). However, it was
not demonstrated how A3B5 could inhibit melanin produc-
tion. In order to elucidate the action mechanism of A3B5, we
first confirmed the inhibitory effect of A3B5 on pigmentation
in vivo with brown guinea pigs. To the UVB-stimulated
hyperpigmented dorsal skin, 10 mg of 0.1% A3B5 was applied
topically. Histological analysis of Fontana-Masson staining
and skin color of the guinea pigs showed decreased melanin
pigment content and lighter skin color (Figure 1a and b),
suggesting that treatment with A3B5 inhibited UVB-induced
pigmentation in the dorsal skin of guinea pigs. The result is
consistent with our previous report (Hwang et al., 2010).
For the in vitro experiments to clarify the inhibitory
mechanism of A3B5, we first determined the cytotoxicity of
A3B5 using the MTT assay with murine melanocytes (Melan-a).
After the cells were incubated in the presence of 10–100mM
A3B5 for 24hours, cell viability was measured. The cell
viability was 480% in the presence of up to 100mM A3B5
(Supplementary Figure S1b online), suggesting that A3B5 has
low cytotoxicity, whereas treatment of A3B5 to melanocytes
reduced melanin content in Melan-a (Figure 1c). For more
precise experiment, we determined the melanin content from
the same number of A3B5-treated and -untreated cells. The
melanin content of A3B5-treated 1106 melanocytes was
decreased compared with that of 1 106 untreated cells
(Figure 1d). These results indicate that A3B5 has inhibitory
effects on melanin synthesis in vitro as well as in vivo.
A3B5 has no inhibitory effect on tyrosinase and TRP-2 activity
but markedly decreases TRP-2 protein level
The first step of melanogenesis is the oxidation of tyrosine by
tyrosinase. Therefore, we investigated the inhibitory effect of
A3B5 on tyrosinase activity. Figure 2a showed that A3B5 had
no significant inhibitory effect on tyrosinase activity, although
it inhibited tyrosinase activity slightly at a concentration of
50 mM. In addition, we determined whether A3B5 inhibited
tyrosinase protein synthesis in Melan-a cells via western
blotting. Daily treatment of Melan-a with A3B5 had no effect
on tyrosinase protein level (Figure 2b). Taken together, A3B5
is an ineffective inhibitor of tyrosinase.
Because A3B5 did not affect the level and activity of tyro-
sinase, we investigated whether A3B5 inhibited TRP-2 acti-
vity. TRP-2 is a member of the TRP family, and it converts
DOPAchrome into DHICA in the melanogenesis pathway
(Tsukamoto et al., 1992). To assess the inhibitory effect of
A3B5 on TRP-2 activity, TRP-2 was purified from Melan-a
cells (Aroca et al., 1992) and the TRP-2 activity was deter-
mined by the decrease of the absorbance at 475 nm due to
the disappearance of L-dopachrome (Ko¨rner and Pawelek,
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Figure 1. N-(3,5-dimethylphenyl)-3-methoxybenzamide (A3B5) inhibits
melanin production in melanocytes. (a) Fontana-Masson staining. Guinea
pigs were exposed to UVB once a week for 3 consecutive weeks. A3B5 (0.1%)
was applied topically to the hyperpigmented areas twice a day for 4 weeks,
starting 1 day after the last tanning treatment. Scale bar¼ 20mm. (b) Skin
color and pigmentation using colorimeter. (c) Cell viability and melanin
production in Melan-a cells at various concentrations. Cells were treated
with A3B5 for 3 days. Melanin content was measured at 405 nm with a
spectrophotometer. Cell viability was quantified by crystal violet staining.
(d) Cells were treated with A3B5 for 3 days, and 1106 cells were
incubated in 1M NaOH. Melanin content was measured at 405 nm with
a spectrophotometer. A representative example of three independent
experiments is shown. Con, control.
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Figure 2. N-(3,5-dimethylphenyl)-3-methoxybenzamide (A3B5) inhibits tyrosinase-related protein 2 (TRP-2) via decreasing of TRP-2 protein but not
tyrosinase. (a) Effect of A3B5 on tyrosinase activity. Tyrosinase was extracted from mushroom and Melan-a to evaluate the effects of A3B5 on tyrosinase
activity. (b) Tyrosinase protein level by A3B5 treatment. Cells were treated with A3B5 for 3 days, and protein level was assessed by western blotting. (c) Effect
of A3B5 on TRP-2 activity. TRP-2 was purified using hydroxyapatite and gel-filtration chromatography from Melan-a cells. The amount of dopachrome
transformed was estimated at 475 nm. (d) Effect of A3B5 on TRP-2 protein level in Melan-a cells. (e) TRP-2 was detected using fluorescence microscopy
after daily treatment with A3B5 for 3 days (original magnification: TRP-2 400, scale bar¼ 10 mm). (f) TRP-2 level in UVB-exposed guinea pig skin.
A representative example of three independent experiments is shown. Con, control.
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1980; Barber et al., 1984; Aroca et al., 1990). The results
showed that A3B5 was an ineffective inhibitor of TRP-2
activity even when we treated 100mM A3B5 (Figure 2c).
Therefore, we investigated whether A3B5 had an inhibitory
effect on TRP-2 protein synthesis in Melan-a cells by western
blotting. Although A3B5 had no effect on tyrosinase protein
level in Melan-a cells (Figure 2b), TRP-2 level was markedly
decreased on days 2 and 3 after daily treatment or one-time
treatment with A3B5, as shown in Figure 2d. Immunohisto-
chemical staining confirmed that A3B5 treatment (50 mM)
decreased TRP-2 level (Figure 2e). In addition, Figure 2f
shows that A3B5 inhibited UVB-induced TRP-2 upregulation
in guinea pig skin. The results suggest that A3B5 may inhibit
melanogenesis through TRP-2 downregulation.
A3B5 induces proteasomal degradation of TRP-2 protein
To determine whether A3B5 regulates TRP-2 transcriptionally
or post-transcriptionally, we measured its mRNA and protein
levels by quantitative real-time PCR analysis and western
blotting, respectively. We treated Melan-a and human
melanocytes with A3B5 for 1, 2, or 3 days. The mRNA levels
of TRP-2 were not changed in A3B5-treated melanocytes
compared with vehicle-treated control melanocytes (Figure
3a and b).
We also measured the mRNA levels of microphthalmia-
associated transcription factor (MITF), a transcription factor
that regulates the expression of tyrosinase and TRP-1 and
TRP-2 (Goding, 2000). A3B5 had no effect on MITF mRNA
levels in both mouse (Melan-a) and human melanocytes
(Supplementary Figure S2a and b online). These results
indicate that A3B5 regulates TRP-2 protein at the post-
transcriptional level. Therefore, we investigated whether
A3B5 could induce TRP-2 protein degradation. Figure 3c
shows that treatment with MG132, a nonselective protea-
some inhibitor, rescued the A3B5-induced repression of
TRP-2 level. In addition, treatment with A3B5 induced the
ubiquitination of TRP-2 relative to vehicle treatment (Figure
3d). Conclusively, our results indicate that A3B5 decreased
TRP-2 protein levels by promoting proteasomal degradation.
A3B5 inhibits UVB-induced TRP-2 upregulation via inhibition
of the p38 pathway
Because UVB upregulates TRP-2 level in melanocytes and
leads to hyperpigmentation (Corre et al., 2006), we examined
whether A3B5 could inhibit UVB-induced upregulation of
TRP-2 level. Melan-a cells were pretreated with A3B5 for
30minutes before UVB exposure and cultured for 2 days with
A3B5 after UVB exposure. A3B5 inhibited UVB-induced
upregulation of TRP-2 protein level (Figure 4a). To determine
whether the inhibition of UVB-induced TRP-2 protein is
regulated at the mRNA level, Melan-a cells were pretreated
with A3B5 for 30minutes before UVB exposure and cultured
for 4 hours with A3B5 after UVB exposure. Interestingly, A3B5
inhibited UVB-induced TRP-2 at the transcriptional level,
unlike constitutively expressed TRP-2 (Figure 4b).
It has been observed that UVB exposure increases the
expression of genes involved in pigmentation such as
tyrosinase, TRP-1, TRP-2, and MITF via p38 and mitogen-
activated protein kinase pathways (Hiroshi et al., 2001; Singh
et al., 2005). Hence, we examined whether A3B5 decreased
UVB-induced signaling activation. Cells were preincubated
with A3B5 for 48 hours before UVB exposure and extra-
cellular signal-regulated kinase and p38 signaling were
measured 30minutes after UVB exposure. The result showed
that A3B5 inhibited UVB-induced p38 activation (Figure 4c),
indicating that A3B5 downregulated UVB-induced TRP-2
protein through the inhibition of p38 activation.
A3B5 inhibits cell proliferation via downregulation of TRP-2
TRP-2 protects melanoma cells from UVB-induced apoptosis
in UV-irradiated human melanomas and melanocytes
(Nishioka et al., 1999), maintaining the melanocyte popula-
tion (Costin et al., 2005). Because A3B5 downregulates TRP-2
protein level (Figure 2d–f), we monitored the effect of A3B5 on
the proliferation of melanocytes and melanoma cells. Before
this examination, we confirmed whether the TRP-2 was
expressed in the melanoma cells. As shown in Figure 5a,
TRP-2 was expressed in them, and its level was decreased by
A3B5 treatment. Additionally, A3B5 inhibited cell prolife-
ration in a concentration- and time-dependent manner in
A375 human melanoma cells (Figure 5b and c). To confirm
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Figure 3. N-(3,5-dimethylphenyl)-3-methoxybenzamide (A3B5) induces
proteasomal degradation of tyrosinase-related protein 2 (TRP-2). Cells were
treated with A3B5 daily and harvested after 1, 2, or 3 days. TRP-2 mRNA
levels were analyzed by quantitative PCR. (a) TRP-2 mRNA levels in
mouse melanocytes (Melan-a). (b) TRP-2 m RNA levels in human normal
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media. (c) Level of TRP-2 protein in proteasome inhibitor-treated cells. Cells
were pretreated with a proteasome inhibitor, MG132, and cultured with
50mM A3B5 for 48 hours. TRP-2 protein was measured by western blotting.
Actin was used to verify equal loading of proteins. (d) Cells were treated
with 50mM A3B5 for 24 hours. TRP-2 was immunoprecipitated, and TRP-2
ubiquitination was measured by western blotting. A representative example
of three independent experiments is shown. Con, control.
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whether downregulation of TRP-2 protein induces inhibition
of melanoma cell growth, we performed an experiment with
small interfering RNA (siRNA). Treatment with siRNA against
TRP-2 inhibited proliferation of melanoma cells (Figure 5d).
The result indicates that TRP-2 is a good target molecule to
inhibit melanoma cell growth and imply that the inhibition
of melanoma cells by A3B5 might be through the reduced
level of TRP-2.
A3B5 decreases cell proliferation via G1 cell cycle arrest
To determine the action mechanisms of A3B5 on the
inhibition of cell proliferation, we analyzed cell cycle
distribution by flow cytometry. Cells were stained with
propidium iodide after the A3B5 treatment for 2 or 3 days and
cell cycle was quantified by FACS analysis. On days 2 and 3,
70 and 75% of A3B5-treated cells had 2N DNA content,
respectively, whereas 59% of untreated cells had 2N DNA
content, suggesting that A3B5 causes melanoma cells to
accumulate in the G1 phase (Figure 5e). This result suggests
that A3B5 might inhibit melanoma cell proliferation because
it arrests melanoma cells in the G1 phase.
To establish the mechanism by which A3B5 induced G1-
phase cell cycle arrest, G1 cell cycle-related protein
expressions were investigated by western blotting. As shown
in Figure 5f, A3B5 decreased cyclin D and cyclin E levels and
enhanced Rb protein level. Rb is a tumor suppressor that
prevents excessive cell growth by inhibiting cell cycle
progression. Taken together, A3B5 inhibited cell growth by
inducing G1 cell cycle arrest by reducing the levels of cyclin
D and cyclin E and increasing the level of Rb.
A3B5 moderately inhibits the growth of melanoma
To evaluate the effect of A3B5 on tumor growth in vivo, we
injected B16F10 mouse melanoma cells into subcutaneous
tissue in the backs of nude mice. Beginning 1 day later, we
administered 100ml of 1mM A3B5 to the tumor region every
other day for 7 days and conducted a tumor biopsy on day 8
(Figure 6a). Figure 6b and c shows that treatment with A3B5
inhibited the growth of the melanoma.
A3B5-treated tumor showed 430% reductions in weight
and size (Figure 6d) and a low level of TRP-2 (Figure 6e)
compared with the one treated with phosphate-buffered
saline (PBS). The result indicates that inhibition of melanoma
growth by A3B5 may result from the downregulation of
TRP-2, which is consistent with in vitro experimental results.
DISCUSSION
Previously, we designed and synthesized a series of biaryl
amides for identification of optimal substituents for each aryl
moiety based on the structure of the hit from random
screening. The selected compound, A3B5, exhibited inhibi-
tory activity on melanin synthesis with low cell toxicity in
Melan-a cells (Hwang et al., 2010). However, the mechanism
by which A3B5 inhibited melanin synthesis was not investi-
gated. Thus, we determined the molecular mechanisms
of A3B5.
Skin and hair color mostly depend on the activity of
enzymes that are associated with melanogenesis in melano-
cytes. Therefore, we investigated the effects of A3B5 on the
activities and levels of tyrosinase and TRP-2, which are
involved in melanin synthesis, to understand the mechanisms
of inhibitory effects of A3B5 on melanin production in
melanocytes. Our data showed that A3B5 had no effects on
tyrosinase and TRP-2 enzyme activities (Figure 2a and c).
Conversely, A3B5 markedly decreased TRP-2 protein level
in melanocytes (Figure 2d–f). Previously, it was reported that
TRP-2-deficient mice have diluted coat color compared
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Figure 4. N-(3,5-dimethylphenyl)-3-methoxybenzamide (A3B5) inhibits
UVB-induced TRP-2 via p38 pathway inhibiting. (a) A3B5 inhibited
UVB-induced TRP-2 protein in Melan-a cells. Melan-a cells were pretreated
for 30minutes before UVB exposure, and TRP-2 protein was measured
48hours after UVB exposure. (b) A3B5 inhibited UVB-induced TRP-2
mRNA expression. Cells were pretreated with A3B5 for 48 hours before UVB
exposure, and TRP-2 mRNA expression was measured 4 hours after UVB
exposure. (c) A3B5 inhibited UVB-induced p38 phosphorylation. Cells were
pretreated with A3B5 for 48 hours before UVB exposure and collected
30minutes after UVB exposure. Actin was used to verify equal loading
of proteins. A representative example of three independent experiments
is shown. Con, control.
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with normal mice (Guyonneau et al., 2004). Thus, melanin
production might be inhibited by downregulation of TRP-2.
Indeed, we demonstrated that downregulation of TRP-2 by
A3B5 could inhibit melanin synthesis (Figures 1 and 2d–f).
This downregulation resulted from the post-transcriptional
regulation of TRP-2, because A3B5 induced TRP-2 ubiquiti-
nation and treatment with MG132 blocked the A3B5-induced
downregulation of TRP-2, without effects on TRP-2 and MITF
mRNA levels (Figure 3 and Supplementary Figure S2a and b
online). Treatment with A3B5 also reduced UVB-induced
TRP-2 and p38 activation (Figure 4a and b). Interes-
tingly, treatment with A3B5 inhibited UV-induced MITF
mRNA expression, whereas it had no effect on constitutively
expressed MITF mRNA (Supplementary Figure S2 online).
In normal conditions, melanin provides natural color to
the skin, hair, iris of the eye, feathers, and scales. Melanin
also provides natural protection against harmful environ-
mental factors such as UV irradiation (Gilchrest et al., 1996).
However, hyperpigmentation is associated with a number of
diseases or conditions, including melasma, Addison’s dis-
ease, and postinflammatory hyperpigmentation (Lynde et al.,
2006; Rigopoulos et al., 2007). Thus, the development of, to
our knowledge, previously unreported preventive and thera-
peutic strategies is very important for protection against
hyperpigmentation. Hydroquinone, kojic acid, arbutin, and
tyrosinase inhibitors have been used frequently in cosmetics
and depigmenting agents for hyperpigmentation. However,
these tyrosinase-targeting agents are highly cytotoxic. A3B5
has relatively low cytotoxicity compared with other depig-
menting agents. In addition, it can be used as a depigmenting
agent in combination with tyrosinase inhibitors because
the target molecule of A3B5 is TRP-2. Moreover, pretreatment
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Figure 5. N-(3,5-dimethylphenyl)-3-methoxybenzamide (A3B5) decreases cell growth via downregulation of cyclin D1 and cyclin E. (a) A3B5 decreased
the protein levels of tyrosinase-related protein 2 (TRP-2) in A375 and B16F10 cells. (b) A3B5 decreased cell proliferation. Cells were counted with a
hemocytometer. (c) Cell proliferation analysis using BrdU in A375 cells at various concentrations and times. (d) Small interfering RNA (siRNA) against
TRP-2 downregulated the TRP-2 level and inhibited melanoma cell proliferation. Cells were treated with siRNA for 2 and 3 days. Cells were counted with
a hemocytometer. Scale bar¼20 mm. (e) Cell cycle analysis by flow cytometry. Cell cycle distribution was analyzed by propidium iodide staining.
Vehicle-treated control cells were cultured for 3 days and harvested. (f) Western blotting of cell cycle-related proteins. Cells were cultured with A3B5
for 3 days. A representative example of three independent experiments is shown. Con, control.
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with A3B5 decreased UV-induced melanin production,
although it did not inhibit melanogenesis in the in vivo
melanoma growth inhibition experiment (Figure 6) because
treatment with A3B5 every other day for 8 days is not enough
to see reduced pigmentation in A3B5-treated tumors. Thus,
A3B5 could be an efficient therapeutic and preventive agent
for hyperpigmentation in the skin.
It has also been demonstrated that TRP-2 is closely
associated with the regulation of cell growth and survival of
melanocytes following UVB exposure (Nishioka et al., 1999;
Fang et al., 2001). Additionally, TRP-2 is also considered an
excellent target for the treatment of melanoma because TRP-2
is most persistently expressed among the melanogenic
proteins, which include tyrosinase, TRP-1, TRP-2, and Pmel
17/Silver, during malignant melanoma progression compared
with initial melanoma stages (Orlow et al., 1998). Therefore,
melanoma vaccines against TRP-2 or TRP-2 peptides were
researched for melanoma therapy, which were found to
trigger strong immune responses through TRP-2-recognized
cytotoxic T lymphocytes (Yamano et al., 2006; Mansour
et al., 2007). However, these therapies based on cytotoxic
T lymphocyte activation were only used for short durations
because immune response generally was suppressed in most
cancer patients (Kusmartsev and Gabrilovich, 2006).
Our results showed that treatment with A3B5 moderately
inhibited melanoma cell growth, without the inhibition of
proliferation in other cancer cells that do not express TRP-2
(data not shown), and decreased tumor weight and size by
30% compared with control treatment with PBS (Figure 6).
A3B5 may have to be used with other drugs for an effective
melanoma treatment, because the effect of A3B5 on the
inhibition of melanoma cell growth was not strong. There-
fore, we are still investigating the nonmelanogenic effect
of A3B5.
In conclusion, we demonstrated that A3B5 markedly
inhibits melanogenesis and moderately inhibits melanoma
cell growth through the degradation of TRP-2, suggesting that
A3B5 could be an effective treatment for melanoma and
specifically for hyperpigmentation.
MATERIALS AND METHODS
Reagents
A3B5 was synthesized using the method previously described
(Hwang et al., 2010). RPMI-1640 and fetal bovine serum were
purchased from Hyclone (South Logan, UT). Medium 154 and
human melanocyte growth supplement were purchased from
Cascade Biologics (Carlsbad, CA). Antibodies of tyrosinase, TRP-2,
and ubiquitin were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). Antibodies of cell cycle-related proteins were
purchased from BD Biosciences (San Diego, CA). A reverse
transcription system for complementary DNA synthesis and the
primer sets of TRP-2 and MITF were purchased from Qiagen (Hilden,
Germany).
Cell culture and UVB irradiation
The murine melanocyte cell line, melan-a, which was created by
Dorothy Bennett (Bennet et al., 1989), was kindly provided by
Dr Hwang at Skin Research Institute, Pacific, Korea, and was grown
as monolayer cultures in RPMI supplemented with 10% fetal bovine
serum, 1% penicillin and streptomycin, and 200nM 12-O-tetra-
decanoylphorbol-13-acetate at 37 1C under a humidified 95–5%
(v/v) mixture of air and CO2.
Cells were irradiated with a bank of two FS20 Lamps (National
Biological, Twinsburg, OH) that emit a continuous spectrum from
270 to 390 nm, with peak emission at 313 nm; B65% of the
radiation was within the UVB (280–320nm) range. The irradiance of
a single bulb averaged 6.25 Jm–2 s–1 at a tube-to-target distance of
8 cm, as measured with a spectroradiometer (model IL1700A;
International Light, Newburyport, MA). The cells were irradiated
with the UVB source at 100 Jm–2 in a minimum amount of PBS after
washing three times with PBS.
MTT assay
The MTT assay was performed as previously described (Wilson and
Spier, 1987). Briefly, cells were added to the 96-well plates in a
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Figure 6. Treatment with N-(3,5-dimethylphenyl)-3-methoxybenzamide
(A3B5) moderately inhibits the growth of melanoma in vivo. (a) Schematic
representation of experimental procedures. B16F10 cells were injected into
the backs of nude mice subcutaneously (s.c.) on day 0. A3B5 or phosphate-
buffered saline (PBS) was administered on days 1, 3, 5, and 7, and the tumors
were analyzed on day 8. (b) Appearance of melanoma injected into the
backs of mice on day 8. (c) The size of the melanoma injected into the backs
of nude mice after treatment with A3B5 or PBS on day 8. (d) Tumor size
and weight on day 8. Tumor volume calculated by volume formula 1/2
LWH, where L is length, W is width, and H is height. (e) Tyrosinase-
related protein 2 (TRP-2) level in tumor. A representative example of three
independent experiments is shown. Differences with *Po0.05 and **Po0.01
were considered statistically significant.
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concentration of 5 103 in a well and cultivated for 24 hours. The
cell viability was determined colorimetrically using MTT reagent.
Determination of melanin content in melan-a cells
Melanin content was determined as previously described (Hosoi
et al., 1995) with minor modifications. After washing the cells
with PBS, cells were lysed with 1ml of 1 N NaOH and homogenized
well. For analysis, 200ml of each cell extract was transferred
into 96-well plates. Relative melanin content was determined by
optical density at 405 nm using a SpectramaxPlus spectrophotometer
(Sunnyvale, CA).
Tyrosinase activity assay
Tyrosinase activity of L-DOPA oxidation was analyzed by measuring
the increase in absorbance at 492 nm. The A3B5 was dissolved in
methanol at various concentrates. Next, 120 ml of 67mM phosphate
buffer containing 8mM L-DOPA (pH 6.8) and 40 ml of each
concentrate of A3B5 was added to a 96-well plate, followed by
mixing with 40 ml of mushroom tyrosinase or melan-a extract.
Tyrosinase activity was analyzed after incubation at 37 1C for
20minutes.
TRP-2 activity assay
TRP-2 activity was determined by measuring the formation of
DHICA from L-dopachrome that was formed from L-DOPA by
oxidation using sodium periodate.
L-Dopachrome was prepared immediately before use by mixing a
solution of L-DOPA in 10mM sodium phosphate, pH 6.0, containing
0.1mM EDTA, with the required volume of a solution of sodium
periodate to achieve a 1:2 molar ratio of L-DOPA to periodate (Aroca
et al., 1990). Dopachrome absorbance was measured at 475 nm.
Quantitative real-time PCR
Total RNAs were isolated from melan-a using the TRIzol reagent
(Invitrogen, Carlsbad, CA). PCR was performed using the Rotergene
6000 (Corbett, Australia) and the QuantiTect SYBR Green PCR Kit
(Qiagen). The amplification program consisted of 1 cycle of 95 1C
with 10minutes hold (hot start), followed by 35 cycles of 95 1C with
20 seconds hold, 55 1C with 20 seconds hold, and 72 1C with
20 seconds hold. After normalization by glyceraldehyde-3-phos-
phate dehydrogenase, the median of target levels of only treated
vehicle to melan-a was used as a calibrator.
UVB-induced hyperpigmentation in brown guinea pigs
UVB-induced hyperpigmentation was induced on the backs of the
brownish guinea pigs weighing B500 g by the methods reported by
Hwang et al. (2010). A3B5 (0.1% A3B5 in propyleneglycol/EtOH/
H2O¼ 5:3:2) was applied topically to the hyperpigmented areas
twice a day for 4 weeks, starting 1 day after the last tanning
treatment. After 4 weeks, skin biopsies were conducted, and
processed for Fontana-Masson staining.
siRNA-mediated knockdown of TRP-2
Human DCT stealth select RNAi (TRP-2 from GenBank under
accession no. MN_001129889) was purchased from Invitrogen.
TRP-2-specific target sequences (TRP-2 siRNA no. DCT-HSS102683
RNAi) were used, antisense 50-AAGAAAGGAACCAUGUUGUAC
AUCC-30 and sense 50-GGAUGUACAACAUGGUUCCUUUCUU-30
for knockdown of endogenous TRP-2. Cells were plated in six-well
dishes and allowed to grow to B50–60% confluence. Cells were
transfected with a nonspecific control siRNA or TRP-2-specific
siRNA by lipofectamine RNAiMax (Invitrogen) and harvested for cell
proliferation or western blot analysis at 2 and 3 days after
transfection.
Animal treatment for tumor study
On day 0, 1 106 cells of B16F10 were injected into the backs of
nude mice (Jackson Lab, Bar Harbor, ME) subcutaneously. On days
1, 3, 5, and 7, 100 ml of 1mM A3B5 or PBS was administered, and the
tumors sizes were analyzed (Tomayko and Patrick Reynolds, 1989)
on day 8. All procedures of animal research were provided in
accordance with the Laboratory Animals Welfare Act, the Guide for
the Care and Use of Laboratory Animals, and the Guidelines and
Policies for Rodent experiment provided by the institutional animal
care and use committee of the School of Medicine, The Catholic
University of Korea (approval no. CUMC-2009-0086-02).
Statistical analysis
Statistical comparisons between groups were made by unpaired two-
sided t-tests.
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